BGM0504 + semaglutide

BGM0504 + semaglutide is a clinical-stage therapeutic comparison and potential combination regimen consisting of BGM0504, an investigational dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, and semaglutide, an approved selective GLP-1 receptor agonist. BGM0504, developed by BrightGene Bio-Medical Technology, is designed to enhance glycemic control and promote weight loss through dual incretin receptor activation. Semaglutide, developed by Novo Nordisk, is a widely prescribed therapy for type 2 diabetes and chronic weight management. While both agents are incretin mimetics, they are primarily evaluated as active comparators in head-to-head clinical trials (such as the Phase III BRIGHT-1 trial in China and Phase III trials in Indonesia) to assess the relative efficacy, safety, and diabetes remission rates of BGM0504 compared to semaglutide.